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1. Introduction 
It is becoming increasingly apparent that some individuals are more susceptible to disease 
than others and more importantly some patients respond to prescribed therapies better than 
others. One of the main reasons for differences in disease susceptibility and the effectiveness 
of drug treatment lies in the genetic makeup of the patient. In addition to many 
environmental factors, genetic variations such as mutations, DNA polymorphisms and 
epigenetic gene regulation are the key players involved in the fate of a person’s health. 
Recent advances in genomics and proteomics are providing novel insights into the complex 
biological process of disease. These insights will ultimately help to tailor personalised 
approaches to the treatment of disease based upon individual molecular “blueprints” of 
their genome and proteome.  
Personalised medicine extends beyond the traditional medical approach in the treatment of 
patients as it aims to identify and target molecular factors contributing to the illness of 
individual patients. The personalised medicine approach is already playing a significant role 
in the way we treat and monitor disease. As many as 10 out of 36 anti-cancer drugs 
approved by the European Union in the last 10 years are considered to be personalised 
medicines (Eicheler, 2010). Breast cancer is one of the best examples whereby a personalised 
medical approach is adopted to detect the expression status of an oestrogen receptor called 
ESR1 in the nucleus of breast cancer cells. Approximately 70% of breast cancer patients 
overexpress this protein which is an important prognostic and predictive marker. Outcomes 
for these patients have been significantly improved by targeting the ESR1 using a hormonal 
treatment known as Tamoxifen. Interestingly this is the most commonly prescribed anti-
cancer treatment in the world, highlighting the importance of a personalised approach in the 
management of disease. 
Microscale technologies are emerging as an enabling platform for the development of novel 
personalised medicines and their broad accessibility. Miniaturised devices have the 
potential to process minute clinical samples and perform extensive genetic, molecular and 
cellular analyses directly on a microfluidic chip. The integration of pre-analytical sample 
handling with a subsequent sample analysis on a single microfluidic device will help to 
achieve highest reproducibility of results and minimise inter-laboratory bias and operators 
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errors.  This will enable rapid investigation of drug effects on normal and diseased cells and 
help to assess the optimal dosage and the combinations of drugs to be prescribed for each 
individual patient. Furthermore, modern microfabrication processes enable mass-
production of low-cost and disposable microfluidic devices making the new therapies more 
affordable.  
In this chapter we discuss the emerging microscale technologies and their potential impact 
on the future of healthcare. We present the upcoming challenges and potential solutions for 
personalised medical technology which is currently being developed at the Biomedical 
Diagnostics Institute (BDI) in Dublin, Ireland. This chapter will focus on microfluidic assays 
for cell-based analyses and will demonstrate the efficacy of novel cell capturing techniques 
with particular emphasis on the detection of ESR1 in breast cancer cells. 
2. Microscale technology 
Since its origins in the 1980s, microfluidics has evolved into an exciting branch of biomedical 
engineering. The growing interest in microfluidics is largely due to its potential to 
revolutionise conventional laboratory handling, processing and bioanalytical techniques. A 
major advantage is their miniaturisation, enabling nano- and picolitre volumes to be 
processed. In the conventional laboratory setting micro- to millilitre volumes are routinely 
handled; however, by significantly reducing this volume, reagent consumption, assay time 
and the related costs are significantly reduced. 
An important feature of microfluidic technology lies in the design of the microfluidic 
channels. Owing to their small dimensions, fluid flows in a strictly laminar i.e., essentially 
without turbulence. Mixing under laminar flow conditions is governed by mere diffusion of 
molecules across the phase interface (Hessel et al., 2005). The laminar character in 
microchannels can be harnessed for fluid control within, e.g. for fine adjustments of 
concentrations of molecules or cells over spatial and temporal microenvironments. As a 
consequence, new cellular applications are made possible with the unprecedented capability 
of closely mimicking in vivo conditions whereby cells are exposed to well-defined chemical 
gradients and changing microenvironments (Englert, 2009; Yu, 2005). These new and 
exciting capabilities become valuable to personalised medicine, both, from the point of view 
of basic research in cancer biology as well as for drug efficacy studies (Kang et al., 2008). The 
process of adaptation of cancer cells to altered microenvironments in vivo, in particular to 
hypoxic conditions, is still not fully understood. Microfluidics can provide a more in-depth 
insight into cell responses under these conditions mimicking specific microenvironments on 
chip (Polinkovsky et al., 2009). Microfluidic devices could therefore enable the study of 
combined effects of altered microenvironments and anticancer drugs on tumour cells and 
help to understand why anticancer drugs lose effectiveness in solid tumours over time 
(Minchinton & Tannock, 2006). 
High level of parallelisation in microfluidic systems is another important feature which 
allows the investigation of a large number of experimental conditions at the same time, 
thereby reducing time and costs compared to conventional laboratory settings. The benefits 
of parallelisation in concert with the miniaturisation make microfluidic devices an excellent 
tool for high throughput analyses. This is a fundamental advantage for disciplines such as 
genomics and proteomics as they rely on large-scale analysis of genes and proteins. High 
throughput techniques provide also a sound foundation for personalised medical research, 
as large numbers of tests at various conditions are required when studying the effects of 
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drugs. Microscale devices, also known as Lab-on-a-Chip, can integrate several laboratory 
unit operations (LUOs) on just one miniaturised platform. The high degree of integration of 
independent LUOs using microfluidics has the potential to revolutionise personalised 
healthcare medicine through drug discovery (Dittrich & Manz, 2006) and point-of-care 
diagnostics (Yager et al., 2006). 
Finally, but not of less importance, many novel fabrication methods are continuously being 
developed. Microfluidic devices are often made of polymers using mass production 
processes such as injection moulding and hot embossing which are optimised for microscale 
dimensions (Voldman et al., 1999). These microfabrication methods allow the devices to be 
produced in large volume and at low cost, which can potentially impact on global health, 
providing the opportunity to fabricate portable and disposable point-of-care devices for 
diagnostics applicable in poorly equipped environments.  
3. Biomedical applications 
Microscale technologies have significantly contributed to numerous biomedical applications 
over the past two decades.  Encouraging advances brought by genomics and proteomics are 
helping to better understand complex molecular mechanisms of diseases. However, there is 
a growing need to translate results from genomic and proteomic research studies into 
clinical practice. This can be achieved by breaking barriers across disciplines and integrating 
various microscale technologies. Molecular profiling technologies are therefore adopting the 
microfluidic approach to solve challenges not amenable to conventional laboratory methods 
(Wlodkowic & Cooper, 2010).  
The sequencing of the human genome has immensely increased our knowledge on human 
health and disease. Genome-wide analyses can now be performed with microfluidic devices 
for on-chip DNA amplification, electrophoresis and DNA hybridisation on microarrays (Yeo 
et al., 2011). Incorporating microfluidic technology not only improves conventional methods 
by reducing diffusion distances and assay times (Wang et al., 2003), but it may also 
significantly enhance assay sensitivities (Liu & Rauch, 2003). The most recent advances in 
microfluidics allow patient specific genetic analyses, such as whole-genome haplotyping 
from a single cell (Fan et al., 2011). Although many of the genomics platforms for the 
analysis of nucleic acids are still at research stages, some are particularly far advanced and 
ready for clinical application.  
Microfluidics based proteomics is by far more challenging compared to on-chip genomics 
(Yeo et al., 2011). Proteins consist of polymers comprising 20 different L-α-amino acids 
and require a three dimensional globular structure to retain their function and activity. In 
addition, purified protein quantities are often limited due to the lack of simple methods 
for amplifying proteins similar to the powerful polymerase chain reaction (PCR) 
technique for nucleic acids. Despite the challenges with protein-based microfluidic 
devices, several applications for protein analysis have been developed including protein 
microarrays (Alvarez et al., 2008; Avseenko et al., 2002), chip-mass spectroscopy interfaces 
(Lazar et al., 2006) protein crystallization (Du et al., 2009) and most recently devices  
for monitoring of temporal expression events in immune cells within a clinical setting 
(Kotz et al.,  2010). 
The microfluidic approach to genomics and proteomics has the potential to help molecular 
profiling technologies to reach the maturity required for tests in clinical practice. It may 
pave the way towards the development of novel medical devices which utilise minute 
www.intechopen.com
 
Advanced Biomedical Engineering 
 
96
quantities of patient sample to analyse DNA and protein signatures in high throughout 
systems. Furthermore, these novel bioassays may potentially allow preliminary self-
screening or even basic treatment by front-line nursing staff, reducing the burden on 
practitioners and hospitals.  
4. Novel approaches for cell trapping on a microfluidic chip 
Microfluidic devices offer a unique opportunity to investigate individual cells derived from 
patients’ samples. Subsets of cell populations involved in pathological processes can be 
monitored and a personalised medical approach can be tailored individually to the patient’s 
needs. Although many different microfluidic cell trapping techniques are currently 
available, they frequently encounter problems such as low cell capture efficiencies, cell 
impairment through non-physiological shear stresses and limited measures of on-chip 
molecular analyses. 
Immobilisation and contact–free cell trapping are the two main cell capture methods which 
are routinely used in microfluidics (Johann, 2006). Both techniques provide unique 
advantages with regard to the capturing of individual cells. Cell immobilisation utilises 
chemical and/or hydrodynamic approaches to trap cells efficiently. The chemical approach 
is based on antibody-protein interactions, whereby cells are immobilised onto surfaces 
which are micro-patterned with antibodies directed against specific proteins expressed on 
the surface of the cell (Anderson et al., 2004). The micro-patterning techniques provide high 
spatial resolution of immobilised cells and allow monitoring of individual cells in response 
to soluble stimuli. The hydrodynamic approach for immobilisation-based cell trapping relies 
on three dimensional surface topography microstructures to sieve cells from fluid flow in a 
microfluidic cavity. Mechanical barriers such as walls or micropores are utilised to retain the 
cells at rest next to a moving fluid (Khademhosseini et al., 2005). One of the main advantages 
of hydrodynamic trapping is its rapid cell immobilisation compared with chemical trapping 
methods as well as the often simple and inexpensive design. 
In contrast to cell immobilisation, contact-free cell trapping uses magnetic, acoustic, 
dielectrophoretic and optical capture techniques to separate and handle cells (Johann, 2006). 
The contact-free techniques allow versatile and flexible cell handling, enabling cell 
positioning, holding, sorting and release with high accuracy and high selectivity (Werner et 
al., 2011). A possible disadvantage of the contact-free techniques is that cells are maintained 
in suspension which prevents adherent cells to grow in cell culture, thereby limiting contact-
free trapping to bioanalytical applications. In addition, cells are exposed to certain 
electromagnetic or mechanical forces and to slightly increased temperatures which may 
have an undesirable effect on the analysed clinical specimen. 
In the following section, we describe two novel hydrodynamic trapping methods which 
employ a sedimentation approach to capture micrometer-sized beads and cells. The first 
method allows the capture of beads within a microscale V-cup array based on a 
centrifugally driven sedimentation. The second method utilises gravitational sedimentation 
to capture cells within a microfluidic trench structure. Both methods facilitate particle 
capture with exceptionally high efficiencies and minimal exposure to hydrodynamic shear 
stress. We show on-chip molecular analysis of the breast cancer related oestrogen receptor 
ESR1 in cell lines as an example for potential personalised medicine applications.  
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4.1 Bead capture and analysis on a centrifugal microfluidic chip 
Although various methods are available for actuating small volumes of liquids in micro-
fluidic devices, the centrifugal microfluidics “lab-on-a-disc” approach offers a unique 
platform well suitable for high-performance point-of-care testing. In addition to forces 
present in most microfluidic systems such as capillarity, the actuation principle utilises 
rotationally induced inertial forces such as the centrifugal, Coriolis and Euler forces to move 
fluids and particles. Under the impact of the centrifugal force, fluids are propelled from the 
centre of rotation to the outer rim of the chip by an “artificial gravity” encountered in the 
rotating system. The centrifugal force scales with the square of the rotational frequency and 
is proportional to the distance from the centre of rotation as well as the radial length of the 
liquid plug. This allows controlling of flow velocities of liquids within the chip by using 
different rotational frequencies.  
A major advantage of this approach is that it enables the design of systems consisting of an 
integrated drive unit, i.e., a motor with a self-contained disposable chip which is 
advantageous when dealing with clinical samples such as blood. Furthermore, the 
centrifugal pumping is widely independent of the physical properties of the liquids such as 
viscosity, conductivity, surface tension and pH. This feature is especially interesting for 
biological applications where samples with a broad range of viscosities and pH values need 
to be processed. Another unique feature of the centrifugal platform is that sample 
preparation steps such as separation of plasma from whole blood can be readily 
implemented by virtue of the density difference between cells and plasma. A 
comprehensive portfolio of LUOs such as valving, mixing and metering has already been 
demonstrated, as well as their integration into full-fledged sample-to-answer systems. For 
reviews of centrifugal microfluidic platforms see Ducrée, 2007 and Madou, 2006. 
The particle trapping method presented here utilizes V-shaped retention elements often 
used in pressure driven microfluidic systems (Di Carlo et al., 2006). The centrifugal disc and 
the particle capture concept are shown in Fig. 1. Briefly, the V-cups are arranged in an array 
format such that there are no direct radial pathways between sample inlet and the end of the 
array. During the capturing process, the particles sediment through the array and are 
trapped when hitting a V-cup structure. Once a cup is occupied a particle, subsequently 
arriving particles deflect from the bulk and get trapped in subsequent cups. By scale 
matching the size of the V-cups to the size of the particles as well as the total number of 
particles introduced with the suspension, the occupancy distribution of particles per cup can 
be adjusted, even to a sharply peaked single-occupancy distribution.  
A major improvement of the centrifugal V-shaped retention scheme is the absence of 
dynamic flow lines which are inherent to pressure driven systems.  The dynamic flow lines 
within the liquid often drag cells suspended in the flow around the V-shaped structures, 
thus leading to low capture efficiencies of 20% and lower (Kim, 2011). In contrast, the 
centrifugal microfluidic device presented here sediments cells under stagnant flow 
conditions. Thus, suspended particles follow straight (radial) paths, with theoretical capture 
efficiencies of 100%. In experiments performed using 10-μm silica beads spun at a rotational 
frequency of 20 Hz, we obtained capture efficiencies greater than 95%. Although there are 
no dynamic flow lines under stagnant flow conditions, additional effects such as the surplus 
of particles captured in one V-shaped retention element, other impact factors such as the 
lateral Coriolis force may deflect the sedimenting particles, reducing the overall capture 
efficiency.  
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Fig. 1. Microfluidic V-cup array on a centrifugal platform. (A) Disc-shaped chip with four 
identical bead capture structures. (B) A drawing showing the design of one of four bead 
capture structures. (C) Magnified view of a V-cup array designed for sedimentation-based 
particle capture induced by centrifugal forces. 
In addition to high capture efficiencies, this centrifugal device provides further benefits 
when compared with microfluidic bead-bed based immunoassays. In fact, beads introduced 
by flow towards a geometrical retention barrier tend to assume random aggregation 
patterns, which provide poorly defined, inhomogeneous flow and assay conditions for each 
bead. Moreover, in other multilayer arrangements, captured beads are located in individual 
focal planes making the readout more difficult. In contrast, using this novel device, the 
location of beads is given by the position of the capture structures, leading to precise flow 
control in the vicinity of each bead. Furthermore, all beads are located in the same focal 
plane which facilitates optical readout by a microscope. Experiments were carried out to 
demonstrate the importance of scale matching between capture element and particles. It has 
been demonstrated that the occupancy distribution of captured beads in V-cups peaks at 
single occupancy when the ratio of cup size to bead size is close to unity. We experimentally 
achieved a single particle occupancy of more than 95% of all occupied V-cups (Burger et al., 
2011).  
The main feature of the centrifugal chip is the highly efficient capture of cells from clinical 
samples and subsequent molecular analysis on the chip. On-chip separation of cells allows 
discriminating between cell types and enables multiplexed immunoassays. In order to 
demonstrate its ability to separate and pinpoint particles to a specific location on the V-cup 
array, the device was loaded with a mixture of polystyrene beads coated with either human 
or mouse IgG antibodies (Fig 2). The mixture of both bead types was trapped in the V-cup 
array. Individual beads were visualised using Cy5 labelled anti-human IgG (red) and FITC 
labelled anti-mouse IgG secondary antibodies (green). 
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Fig. 2. On-chip immunoassay performed on the centrifugal platform. (A) Beads coated with 
human or mouse IgG antibodies were separated on the V-cup array and visualised using 
Cy5 labelled anti-human IgG and FITC labelled anti-mouse IgG secondary antibodies. The 
figure shows superimposed bright field, Cy5 fluorescent and FITC fluorescent images. Scale 
bar is 100 µm. 
4.2 Cell capture and molecular analysis on a novel microfluidic trench chip  
The second micro-particle capture approach which we recently developed utilises 
gravitational sedimentation in conjunction with a microfluidic trench structure for efficient 
cell capture and subsequent molecular analyses. The device was fabricated using standard 
soft lithography methods and consists of a network of microfluidic channels leading to a cell 
capture chamber. The design utilizes a microfluidic trench structure with characteristic 
dimensions (220 µm deep, 100 µm x 400 µm cross section) as a region of minimal flow for 
hydrodynamic cell capture (Fig. 3). Cells are loaded onto the microfluidic chip and dragged 
with the flow through the microfluidic channels into the capture chamber where the cells 
are effectively trapped. The widened section of the flow channel reduces the flow velocity, 
providing sufficient time for cells to irreversibly sediment into the trench. This is a highly 
efficient, merely sedimentation-based cell capture method, whereby experiments with HeLa 
and MCF7 cells show capture efficiencies close to 100% at flow velocities of 20 µm s-1 
(Dimov et al., 2011). 
Cell loading onto the chip and flow velocities within the microfluidic channels are 
controlled by fluid levels within a pipette tip at the inlet of the chip. The pipette tip serves as 
an open liquid column generating hydrostatic pressure within the microfluidic channels. 
Flow velocities within the microfluidic channels and the trench structure were simulated 
using a computational fluid dynamics (CFD) approach (Fig. 3). The CFD simulation 
revealed decreasing flow velocities towards the base of the trench. Flow velocities at the 
bottom of the trench were calculated to be three orders of magnitude lower than in the 
channel above. Cells entering the low velocity region were therefore effectively retained at 
the base of the trench. Importantly, the minute flow velocities at the base of the trench 
significantly reduce shear stresses exerted on cells. Such shear-protected regions provide an 
advantage over other microfluidic cell retention methods, in particular in biomedical 
applications. Fluid shear stresses may considerably modify the state of captured cells and 
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introduce a bias into microfluidic bioassays. Minimising shear stress exposure may have a 
positive effect on microfluidic cell culture and opens up a route to analyse highly sensitive 
cells such as stem cells directly on this platform. 
 
              
Fig. 3. Microfluidic trench structure: design and working principle. (A) CFD simulation of 
flow velocities within the trench structure. (B) Cells are captured based on the sedimentation 
of cells to the bottom of a microscale trench (side view). (C) Photograph of HeLa cells 
captured within the microfluidic trench structure (top view). 
An important feature of the microfluidic trench device is its capability to perform several 
different bioassays in parallel (Kijanka et al., 2009). Its key characteristic is a simple loading 
of liquids onto the chip, hence enabling rapid replacement of reagents within the trench for 
multi-step bioassays. Here we demonstrate an immunoassay performed directly on the chip. 
Cells and reagents were loaded onto the chip. The reagents were allowed to interact with 
captured cells through diffusive mixing within the trench structure. Finally, cell staining 
was visualised using a fluorescent microscope (Fig. 4).  
 
 
Fig. 4. On-chip immunoassay performed on the microfluidic trench platform. (A) MCF7 and 
HeLa cells were captured within the microfluidic trench structure. Cells were stained with 
propidium iodide (PI) to mark nuclei of all cells (red) and with anti-oestrogen receptor 
antibodies (ESR1) to visualise ESR1 expression (green). (B) MCF7 cells show specific nuclear 
staining for oestrogen receptor ESR1.  
A B
C 
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To determine the ESR1 levels in mammalian cells, cervical cancer cells (HeLa) and breast 
cancer cells (MCF7) were captured on the chip (Fig.4). Cells resting within the trench structure 
were exposed to a multi-step immunostaining protocol. Initially, cells were fixed with a 4% 
formaldehyde solution and permeabilised with ice cold acetone. These permeabilised cells 
were then treated with a 4% skimmed milk (Marvel) blocking solution to avoid non-specific 
binding. Both cells types were then incubated with a mouse anti-ESR1 antibody and 
corresponding anti-mouse secondary antibody labelled with the Alexa488 fluorophore. Since 
we expected a nuclear expression of ESR1, cells were counter-stained with propidium iodide 
(PI), a fluorophore with a specific red staining at cell nuclei. As shown in Fig. 4, both cell types 
were successfully immobilised in the microfluidic device and the immunostaining was 
performed. The counter-stain with PI revealed the location of nuclei within the cells (red). 
However, only the MCF7 cells, and not HeLa cells showed ESR1 expression when treated with 
specific, fluorescently labelled antibodies (green). The results show the ability of the device to 
perform complex molecular protocols directly on the chip. In this immunostaining experiment 
we could detect breast cancer related oestrogen receptor ESR1 in the breast cancer cell line 
MCF7 and the absence of this receptor in cervical cancer cell line HeLa. 
5. Conclusion 
Personalised medicine is gaining significant momentum in the medical field as a means to 
tailor patient care, based on a unique molecular signature. The application of novel methods 
to assess patient samples through minimally invasive technology will emerge as key tool in 
the diagnosis and monitoring of disease in the future. Low-cost, mass produced microfluidic 
devices have the capability to process patient samples in a highly efficient manner and 
enable the detection of markers of disease through the manipulation of cells under 
controlled microfluidic conditions. These technologies provide a suitable platform for the 
investigation of cells both on a genomic and proteomic level. 
Current interdisciplinary research efforts focus on faster, accurate, reliable, and reproducible 
microfluidic tests applicable to clinical settings. In this chapter we described two novel 
approaches for cell capture and subsequent molecular analysis in a microfluidic chip. Both 
microfluidic devices demonstrate high particle capture efficiencies with the potential for 
application in diagnostic bead based immunoassays. Minimising shear stress exposure 
maintains the physiological integrity of cells within these microfluidic devices, thus helping 
to recreate in vivo conditions on chip. As personalised medicine emerges as the key 
approach to monitor and treat disease in the future, the accessibility and cost-effectiveness 
of these personalised tests will be critical for its success. 
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